Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 4/20 | 0.69 |
| ▸ | KDR | P35968 | 10/20 | 0.60 |
| ▸ | FLT1 | P17948 | 7/20 | 0.60 |
| ▸ | EGFR | P00533 | 7/20 | 0.60 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.60 |
| ▸ | FLT4 | P35916 | 5/20 | 0.60 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.57 |
| ▸ | EHMT1 | Q9H9B1 | 2/20 | 0.57 |
| ▸ | SRC | P12931 | 5/20 | 0.54 |
| ▸ | MET | P08581 | 5/20 | 0.54 |
| ▸ | CIT | O14578 | 2/20 | 0.54 |
| ▸ | EPHB6 | O15197 | 2/20 | 0.54 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.54 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.54 |
| ▸ | STK10 | O94804 | 2/20 | 0.54 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.54 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.54 |
| ▸ | ABL1 | P00519 | 2/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12469296 | 0.97 | AXL (0.73) | AXLKDRFLT1EGFRFGFR1 | |
| SCHEMBL6431410 | 0.87 | EGFR (0.78) | AXLKDRFLT1EGFRFGFR1 | |
| SCHEMBL6430831 | 0.87 | EGFR (0.78) | AXLKDRFLT1EGFRFGFR1 | |
| Hydrochloric Acid SCHEMBL6882131 | 0.86 | EGFR (0.77) | AXLKDRFLT1EGFRFGFR1 | |
| SCHEMBL12469293 | 0.85 | KDR (0.59) | AXLKDRFLT1EGFRFGFR1 | |
| SCHEMBL6431249 | 0.82 | RET (0.60) | AXLKDRFLT1EGFRFGFR1 | |
| SCHEMBL14289180 | 0.82 | AXL (1.00) | AXLKDRFLT1EGFRFGFR1 | |
| SCHEMBL166239 | 0.82 | AXL (1.00) | AXLKDRFLT1EGFRFGFR1 | |
| SCHEMBL30000966 | 0.82 | AXL (1.00) | AXLKDRFLT1EGFRFGFR1 | |
| SCHEMBL6431449 | 0.82 | FLT1 (0.71) | AXLKDRFLT1EGFRFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2768796-B1 | PROCESS FOR PREPARING QUINOLINE DERIVATIVES | EXELIXIS INC (US) | 2019-11-20 | — | — | EP | disclosed |
| US-9969692-B2 | Process for preparing quinoline derivatives | EXELIXIS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20160229805-A1 | Process for Preparing Quinoline Derivatives | EXELIXIS, INC. | 2016-08-11 | — | — | US | disclosed |
| US-9365516-B2 | Process for preparing quinoline derivatives | EXELIXIS, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20140256938-A1 | Process for Preparing Quinoline Derivatives | EXELIXIS, INC. | 2014-09-11 | — | — | US | disclosed |
| EP-2768796-A1 | PROCESS FOR PREPARING QUINOLINE DERIVATIVES | Exelixis, Inc. (US) | 2014-08-27 | — | — | EP | disclosed |
| US-20140066444-A1 | Method of Treating Cancer | EXELIXIS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140057908-A1 | Method of Treating Cancer | EXELIXIS, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| EP-2621482-A1 | DUAL INHIBITORS OF MET AND VEGF FOR THE TREATMENT OF CASTRATION RESISTANT PROSTATE CANCER AND OSTEOBLASTIC BONE METASTASES | Exelixis, Inc. (US) | 2013-08-07 | — | — | EP | disclosed |
| EP-2621483-A1 | DUAL INHIBITORS OF MET AND VEGF FOR THE TREATMENT OF CASTRATION RESISTANT PROSTATE CANCER AND OSTEOBLASTIC BONE METASTASES | Exelixis, Inc. (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20130197230-A1 | METHODS OF PREPARING QUINOLINE DERIVATIVES | EXELIXIS, INC. | 2013-08-01 | — | — | US | disclosed |
| WO-2013059788-A1 | PROCESS FOR PREPARING QUINOLINE DERIVATIVES | EXELIXIS, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| WO-2012044574-A1 | DUAL INHIBITORS OF MET AND VEGF FOR THE TREATMENT OF CASTRATION RESISTANT PROSTATE CANCER AND OSTEOBLASTIC BONE METASTASES | EXELIXIS, INC. (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012044577-A1 | DUAL INHIBITORS OF MET AND VEGF FOR THE TREATMENT OF CASTRATION RESISTANT PROSTATE CANCER AND OSTEOBLASTIC BONE METASTASES | EXELIXIS, INC. (US) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229805-A1 | Process for Preparing Quinoline Derivatives | C5, C1S, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | AXL 4217/4885KDR 4364/4885FLT1 3378/4885 |
| US-20130197230-A1 | METHODS OF PREPARING QUINOLINE DERIVATIVES | F12, RECQL, H1-2 | AXL 3708/4885KDR 2714/4885FLT1 2170/4885 |
| US-20140256938-A1 | Process for Preparing Quinoline Derivatives | C5, C1S, C1R | AXL 4220/4885KDR 4335/4885FLT1 3534/4885 |
| US-20140066444-A1 | Method of Treating Cancer | MET, HGF, ACP3 | AXL 2179/4885KDR 8/4885FLT1 9/4885 |
| US-20140057908-A1 | Method of Treating Cancer | MET, HGF, ACP3 | AXL 2179/4885KDR 8/4885FLT1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.